The patent application for the new coronavirus vaccine (Ad5-nCoV vaccine), jointly developed by Chen Wei of the Chinese Military Sciences Medical Academy and CanSino Biosciences company, has been approved. This was China's first patent for the novel coronavirus. The patent document filed on March 18th was approved on August 11th.
The recombinant novel coronavirus vaccine developed by the team led by Chen Wei has completed the 1st phase domestically and the 2nd phase clinical trial in the world. Thus, the safety of the vaccine and whether it enhances immunity was confirmed. The 3rd phase international clinical trial of the vaccine is under control. According to the information on the website of the Chinese National Intellectual Property Administration, the vaccine can be mass produced in a very short time in the event of an epidemic.
CanSino said on Sunday that the granting of the patent further confirms the vaccine's efficacy and safety, and that intellectual property rights (IPR) have emerged. Tao Lina, a Shanghai-based vaccine specialist, said the patent grant would likely facilitate the marketing process. He added that an officially issued patent would increase market confidence, especially for COVID-19 vaccines developed by China in the international market.
On the other hand, Indian Prime Minister Narendra Modi said in his Independence Day speech on Saturday that India is ready to mass produce COVID-19 vaccines. According to Modi, three coronavirus vaccines are being tested in India.
Russian President Vladimir Putin announced last week that the world's first vaccine against the new coronavirus was developed, adding that his daughter had already been vaccinated.
Russian Health Minister Mikhail Murashko announced last week that the first batch of the vaccine developed by Russia's Gamaleya Research Institute will be ready for use within two weeks.
Hibya News Agency